Literature DB >> 22275370

Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways.

Lisbeth M Andersen1, Peter A Andreasen, Ivan Svendsen, Janneke Keemink, Henrik Østergaard, Egon Persson.   

Abstract

In the absence of its cofactor tissue factor (TF), coagulation factor VIIa (FVIIa) predominantly exists in a zymogen-like, catalytically incompetent state. Here we demonstrate that conformation-specific monoclonal antibodies (mAbs) can be used to characterize structural features determining the activity of FVIIa. We isolated two classes of mAbs, which both increased the catalytic efficiency of FVIIa more than 150-fold. The effects of the antibodies were retained with a FVIIa variant, which has been shown to be inert to allosteric activation by the natural activator TF, suggesting that the antibodies and TF employ distinct mechanisms of activation. The antibodies could be classified into two groups based on their patterns of affinities for different conformations of FVIIa. Whereas one class of antibodies affected both the K(m) and k(cat), the other class mainly affected the K(m). The antibody-induced activity enhancement could be traced to maturation of the S1 substrate binding pocket and the oxyanion hole, evident by an increased affinity for p-aminobenzamidine, an increased rate of antithrombin inhibition, an increased rate of incorporation of diisopropylfluorophosphate, and an enhanced fraction of molecules with a buried N terminus of the catalytic domain in the presence of antibodies. As demonstrated by site-directed mutagenesis, the two groups of antibodies appear to have overlapping, although clearly different, epitopes in the 170-loop. Our findings suggest that binding of ligands to specific residues in the 170-loop or its spatial vicinity may stabilize the S1 pocket and the oxyanion hole, and they may have general implications for the molecular understanding of FVIIa regulatory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22275370      PMCID: PMC3308810          DOI: 10.1074/jbc.M111.312330

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 2.  Serine protease mechanism and specificity.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

3.  Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor.

Authors:  B B Sorensen; E Persson; P O Freskgârd; M Kjalke; M Ezban; T Williams; L V Rao
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

4.  Comparative studies on the inhibition of trypsin, plasmin, and thrombin by derivatives of benzylamine and benzamidine.

Authors:  F Markwardt; H Landmann; P Walsmann
Journal:  Eur J Biochem       Date:  1968-12-05

5.  Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

Authors:  E Persson; M Kjalke; O H Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

6.  Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor.

Authors:  E Persson; L S Nielsen; O H Olsen
Journal:  Biochemistry       Date:  2001-03-20       Impact factor: 3.162

7.  Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity.

Authors:  E Persson; H Bak; O H Olsen
Journal:  J Biol Chem       Date:  2001-06-01       Impact factor: 5.157

8.  Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement.

Authors:  Egon Persson; Helle Bak; Anette Østergaard; Ole H Olsen
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  Role of zymogenicity-determining residues of coagulation factor VII/VIIa in cofactor interaction and macromolecular substrate recognition.

Authors:  Ramona J Petrovan; Wolfram Ruf
Journal:  Biochemistry       Date:  2002-07-30       Impact factor: 3.162

10.  An antibody specific for coagulation factor IX enhances the activity of the intrinsic factor X-activating complex.

Authors:  Randolf J Kerschbaumer; Klaudia Riedrich; Martina Kral; Katalin Varadi; Friedrich Dorner; Jan Rosing; Friedrich Scheiflinger
Journal:  J Biol Chem       Date:  2004-07-20       Impact factor: 5.157

View more
  3 in total

1.  Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies.

Authors:  Kaushik Dutta; Avanish K Varshney; Matthew C Franklin; Michael Goger; Xiaobo Wang; Bettina C Fries
Journal:  J Biol Chem       Date:  2015-01-08       Impact factor: 5.157

2.  The spatial structure of cell signaling systems.

Authors:  Ruth Nussinov
Journal:  Phys Biol       Date:  2013-08-02       Impact factor: 2.583

3.  Engineering of a membrane-triggered activity switch in coagulation factor VIIa.

Authors:  Anders L Nielsen; Anders B Sorensen; Heidi L Holmberg; Prafull S Gandhi; Johan Karlsson; Jens Buchardt; Kasper Lamberth; Mads Kjelgaard-Hansen; Carsten Dan Ley; Brit B Sørensen; Wolfram Ruf; Ole H Olsen; Henrik Østergaard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.